Johnson & Johnson Reports Phase 3 extension Data for Risdiplam in Asthma

Johnson & Johnson today announced Phase 3 extension results for risdiplam in patients with asthma. The study demonstrated that risdiplam demonstrates durable remissions compared to standard of care or placebo. These results provide important insights into the treatment of asthma and support the continued development of risdiplam in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.